122 related articles for article (PubMed ID: 38177074)
21. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
22. Low-grade epilepsy-associated neuroepithelial tumours with a prominent oligodendroglioma-like component: The diagnostic challenges.
Métais A; Appay R; Pagès M; Gallardo C; Silva K; Siegfried A; Perbet R; Maurage CA; Scavarda D; Fina F; Uro-Coste E; Riffaud L; Colin C; Figarella-Branger D;
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12769. PubMed ID: 34551121
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of Expression the Arginine Pathway Enzymes in Childhood Brain Tumours to Determine Susceptibility to Therapeutic Arginine Depletion.
Bishop E; Dimitrova M; Froggatt A; Estevez-Cebrero M; Storer LCD; Mussai F; Paine S; Grundy RG; Dandapani M
Biomed Res Int; 2022; 2022():9008685. PubMed ID: 35782058
[TBL] [Abstract][Full Text] [Related]
24. Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.
Tarkkonen KM; Nilsson EM; Kähkönen TE; Dey JH; Heikkilä JE; Tuomela JM; Liu Q; Hynes NE; Härkönen PL
PLoS One; 2012; 7(11):e49970. PubMed ID: 23185502
[TBL] [Abstract][Full Text] [Related]
25. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
26. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract][Full Text] [Related]
27. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
[TBL] [Abstract][Full Text] [Related]
28. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Guillevin R; Menuel C; Taillibert S; Capelle L; Costalat R; Abud L; Habas C; De Marco G; Hoang-Xuan K; Chiras J; Vallée JN
Br J Cancer; 2011 Jun; 104(12):1854-61. PubMed ID: 21610707
[TBL] [Abstract][Full Text] [Related]
29. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.
Hughes SE
Cardiovasc Res; 1996 Sep; 32(3):557-69. PubMed ID: 8881516
[TBL] [Abstract][Full Text] [Related]
30. Pediatric spinal pilocytic astrocytomas form a distinct epigenetic subclass from pilocytic astrocytomas of other locations and diffuse leptomeningeal glioneuronal tumours.
Métais A; Bouchoucha Y; Kergrohen T; Dangouloff-Ros V; Maynadier X; Ajlil Y; Carton M; Yacoub W; Saffroy R; Figarella-Branger D; Uro-Coste E; Sevely A; Larrieu-Ciron D; Faisant M; Machet MC; Wahler E; Roux A; Benichi S; Beccaria K; Blauwblomme T; Boddaert N; Chrétien F; Doz F; Dufour C; Grill J; Debily MA; Varlet P; Tauziède-Espariat A
Acta Neuropathol; 2023 Jan; 145(1):83-95. PubMed ID: 36264505
[TBL] [Abstract][Full Text] [Related]
31. Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death.
Ahrendsen JT; Sinai C; Meredith DM; Malinowski SW; Cooney TM; Bandopadhayay P; Ligon KL; Alexandrescu S
J Neuropathol Exp Neurol; 2021 Nov; 80(11):1052–1059. PubMed ID: 34580728
[TBL] [Abstract][Full Text] [Related]
32. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
[TBL] [Abstract][Full Text] [Related]
33. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
34. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
[TBL] [Abstract][Full Text] [Related]
35. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
36. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
37. Association of the FGFR1 mutation with spontaneous hemorrhage in low-grade gliomas in pediatric and young adult patients.
Ishi Y; Yamaguchi S; Hatanaka KC; Okamoto M; Motegi H; Kobayashi H; Terasaka S; Houkin K
J Neurosurg; 2020 Feb; 134(3):733-741. PubMed ID: 32059187
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
39. [FGFR3 overexpression is a relevant alteration in colorectal cancer].
Fromme JE; Schildhaus HU
Pathologe; 2018 Dec; 39(Suppl 2):189-192. PubMed ID: 30267148
[TBL] [Abstract][Full Text] [Related]
40. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
